English हिन्दी
Connect with us

Latest Science News

World AIDS Day 2018: Myths and facts about HIV

Published

on

World AIDS Day 2021: Why HIV virus is still a pandemic? What is the status of HIV in India?

[vc_row][vc_column][vc_column_text]The theme of the 30th anniversary of World AIDS Day, which shows support for people living with HIV and commemorates those who have died, is “Know your Status.”

According to the Centres for Disease Control (CDC), people between the ages of 13 and 64 should get tested for HIV at least once as part of routine health care. HIV testing allows you to know for sure whether the virus is there in your body or not, and seek medical help if you are HIV-positive, or continue taking steps to avoid getting the deadly virus.

AIDS stands for Acquired Immune Deficiency Syndrome. It is caused by the human immunodeficiency virus (HIV) which enters the body from outside.

This virus affects our immunity system and decreases the ability of the body to defend itself against infections and diseases. HIV virus is transmitted through contact with infected blood, semen, vaginal fluids or even breast milk.

As sexual transmission is one of the ways the HIV infection spreads, along with the fact that it remains incurable so far, there is a certain social stigma attached to HIV positive patients.

Here are some myths that people believe HIV can spread through –

  • They think HIV/AIDS is spread by kissing and hugging.
  • Another false belief is that you can get HIV by sharing food or water.
  • You can contract HIV/AIDS if someone sneezes or coughs.
  • People think HIV can be spread by mosquito bite.
  • One of the biggest false beliefs is that you can’t have a baby if you are HIV positive.

Here are some facts to break these myths –

  • AIDS cannot be transmitted by sharing food and eating utensils with HIV positive person.
  • HIV cannot spread through saliva (Kissing), hugging or shaking hands.
  • The myth that women with HIV cannot have a baby is false. There are a number of options for women who are HIV positive to have healthy babies. HIV positive women who become pregnant are encouraged to speak with their doctor about the best treatment options available. Early prenatal care is important to reduce the likelihood of mother to child transmission.
  • It cannot spread through the sweat of infected person.
  • AIDS is not caused by mosquito bite.

Some numerical data facts about AIDS –

  • About 35 million people have died from AIDS-related illnesses since 1981, including 940,000 in 2017.
  • Every week, almost 7,000 young women aged between 15 and 24 are infected with HIV.
  • An estimated 77 million people have become infected with HIV since the start of the epidemic in 1981, including 1.8 million in 2017.
  • South Africa has the world’s highest HIV prevalence, with almost one in five people infected.
  • United Nations Programme on HIV and AIDS (UNAIDS) wants nine in 10 people to know their status by 2020.

We need to support the HIV campaign of this year “Know your status,” and let the mission UNAIDS be successful.[/vc_column_text][/vc_column][/vc_row]

Latest Science News

ISRO-European Space Agency sign agreement for advancing human spaceflight

Dr. Aschbacher expressed gratitude to Dr. Somanath for his address at the ESA Council, noting that the agreement lays a solid foundation for ongoing cooperation between the two agencies.

Published

on

ISRO on Saturday announced that it has signed an agreement with the European Space Agency (ESA) to collaborate on astronaut training, mission execution, and research initiatives. The agreement was formalised by ISRO Chairman Dr. S Somanath and ESA Director General Dr. Josef Aschbacher.

This partnership establishes a framework for cooperative efforts in human space exploration and research, focusing on areas such as astronaut training, experiment development and integration using ESA facilities on the International Space Station (ISS), human and biomedical research experiments, and joint educational outreach programs, according to ISRO’s statement.

For the upcoming Axiom-4 mission, where ISRO’s Gaganyatri will be part of the crew alongside an ESA astronaut, both organizations will work together to conduct experiments proposed by Indian Principal Investigators on the ISS.

Moreover, the collaboration aims to include participation in ESA’s human physiological studies, technology demonstration experiments, and further joint educational outreach initiatives.

During the announcement, Dr. Somanath emphasised that ISRO has developed a roadmap for human spaceflight activities, and with the approval of the Bharatiya Antariksh Station (BAS), India’s planned indigenous space station, there is an opportunity to foster interoperability between human spaceflight programs.

Dr. Aschbacher expressed gratitude to Dr. Somanath for his address at the ESA Council, noting that the agreement lays a solid foundation for ongoing cooperation between the two agencies.

The leadership of both ISRO and ESA conveyed their satisfaction with the progress of the joint projects related to the Axiom-4 mission and emphasized the importance of continuing collaborative efforts in human spaceflight in the future, according to ISRO’s statement.

ISRO has stated that the newly signed agreement creates a framework for collaboration in human space exploration and research. This partnership emphasizes astronaut training, support for experiment development and integration—which includes utilising ESA facilities on the International Space Station—along with conducting human and biomedical research experiments and engaging in joint educational and outreach initiatives.

In preparation for the upcoming Axiom-4 mission, which will feature ISRO’s Gaganyatri alongside an ESA astronaut, both agencies are working together to implement experiments proposed by Indian Principal Investigators on the ISS. Additionally, ISRO is actively pursuing participation in ESA’s human physiological studies, technology demonstration experiments, and joint educational outreach efforts.

Continue Reading

India News

ISRO-NASA mission: Astronaut Shubhanshu Shukla to be 2nd Indian to travel to space, 40 years after Rakesh Sharma

Nair serves as the contingency astronaut, ready to step in should Shukla be unable to proceed.

Published

on

Group Captain Subhanshu Shukla is poised to become the first Indian in four decades to journey into space, with the Indian Space Research Organisation (ISRO) designating him as the ‘primary’ astronaut for the inaugural ISRO-NASA mission to the International Space Station, anticipated to commence after October this year.

On Friday, ISRO announced the selection of Shukla, 39, and Group Captain Prasanth Balakrishnan Nair, 48, for the Axiom-4 mission, appointing Shukla as the ‘prime’ astronaut, implying his primary role in traveling to the ISS. Nair serves as the contingency astronaut, ready to step in should Shukla be unable to proceed.

To date, Rakesh Sharma remains the sole Indian to have ventured into space, having done so in 1984 as a wing commander aboard a Soviet spacecraft. Shukla and Nair are among four Indian Air Force officers chosen for India’s pioneering manned space mission, Gaganyaan, slated for a tentative launch next year.

According to an ISRO official, the duo will engage in eight weeks of mission-specific training. The Axiom-4 mission, orchestrated by private space enterprise Axiom Space in collaboration with NASA, will be propelled by a SpaceX rocket. Joining Shukla will be three astronauts from Poland, Hungary, and the United States. This mission is the result of an accord between New Delhi and Washington during Prime Minister Narendra Modi’s U.S. visit last year.

The Axiom-4 spacecraft will remain affixed to the ISS for a duration of 14 days, ferrying not just astronauts but also cargo and supplies to the station. A launch date has not been pinpointed. According to NASA’s website, the mission is planned for no earlier than October 2024, but Poland’s space agency recently suggested the mission could slip into next year. Shukla is a fighter pilot from Lucknow in Uttar Pradesh and was commissioned into the IAF in 2006.

He has spent more than 2,000 hours on many IAF fighter jets, including Sukhoi-30 MKIs, MiG-21s, MiG-29s, Jaguars, Hawks, Dorniers, and the AN-32 aircraft. Nair, who won the Sword of Honour at the Air Force Academy, was commissioned into the IAF in 1998. A category ‘A’ flying instructor and test pilot, having flown over 3,000 hours, he is an alumnus of the United States Staff College and has commanded a Sukhoi-30 squadron.

The Gaganyaan mission of India draws on the experience and expertise gained from the Indian astronauts’ experiences with the ISS mission. “This is a collaborative effort between the two countries with the United States, and it benefits both,” said Somanath, chairman of ISRO, in 2023. “Training in the US and the subsequent discussions will enhance a lot in designing our Gaganyaan mission.”

Continue Reading

India News

President Droupadi Murmu launches India’s first homegrown CAR T-cell therapy for cancer treatment

The gene-based therapy, which is developed by the IIT Bombay and Tata Memorial Centre, is being rolled out in India at about one-tenth of its price outside the country.

Published

on

By

President Droupadi Murmu on Thursday launched India’s first indigenously-developed CAR T-cell therapy, a gene-based therapy, for cancer treatment, hailing it as a breakthrough that provides new hope for humankind in the battle against the diseases.

Speaking at the launch event at the Indian Institute of Technology (IIT) Bombay, Murmu said the indigenous development of the CAR T-cell therapy was an example of the Make in India initiative.  

The gene-based therapy, which is developed by the IIT Bombay and Tata Memorial Centre, is being rolled out in India at about one-tenth of its price outside the country, as per the senior official.

In CAR T-cell therapy, a patient’s T-cells, which is a type of immune system cell or stem cell, are modified in the laboratory and inserted back into the patient to attack and destroy cancer cells after editing the stem cell.

The NexCAR19 CAR T-cell therapy, the country’s first Made in India CAR T-cell therapy, is expected to bring down the cost of treatment significantly.

During her speech, Murmu said that this therapy is considered a phenomenal advance in medical sciences. The development of this therapy is also an example of the Make in India initiative and speaks volumes about Indian scientists and physicians, she added.

The launch of India’s first gene therapy is a significant breakthrough in the battle against cancer. As this line of treatment, named CAR T-cell therapy, is accessible and affordable, it provides a new hope for the whole of humankind, President Murmu further added.

The Tata Memorial Centre director Sudeep Gupta said the CAR T-cell therapy was enormously expensive and out of the reach of an overwhelming majority of people.

Asserting that, he said NexCar19 needs to be custom manufactured for every patient under the most stringent conditions, but it has been rolled out at approximately one-tenth of the price at which it is available outside India.

The treatment costs approximately Rs 4 crore abroad against Rs 30 lakh in India, said IIT Bombay director Prof Subhasis Chaudhuri.

He further said that the low-cost CAR T-cell therapy was a huge achievement for the country and cancer patients, and places India firmly on the global map of cell and gene therapy.

Comparing the achievement of Chandrayaan-3 with CAR T-cell therapy, Chaudhuri asserted that CAR-T cell therapy heralds India’s entry into the cell and genetic engineering group.

The Tata Memorial Centre director Gupta said the treatment will help some 20,000 Indians every year, and its rollout is a milestone in the field of cancer care and genetic engineering.

He added the CAR T-cell was not only a scientific achievement of the highest order but also had immense practical application. NexCAR19 will save many, many lives and wipe many, many tears, he emphasised.

Continue Reading

Trending

© Copyright 2022 APNLIVE.com